Evaluation of 17 patients with COVID‐19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA, and Brescia‐COVID respiratory severity scale (BCRSS) scoring systems

COVID‐19 pandemic has been affecting the whole world by increasing morbidity and mortality rates day by day. Treatment algorithms have been attempted as parallel to the increasing experience with COVID‐19. In the pathogenesis of this virus pro‐inflammatory cytokine storm has been called to have the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2021-03, Vol.93 (3), p.1532-1537
Main Authors: Erden, Abdulsamet, Ozdemir, Bahar, Karakas, Ozlem, Mutlu, Nevzat Mehmet, Izdes, Seval, Kalem, Ayse Kaya, Bilir, Yeşim Aybar, Aypak, Adalet, Akinci, Esragul, Guner, Rahmet, Kucuksahin, Orhan
Format: Article
Language:English
Subjects:
Algorithms
anakinra
Antiviral agents
Antiviral Agents - therapeutic use
Brescia‐COVID respiratory severity scale
Comorbidity
COVID-19
COVID-19 - drug therapy
COVID-19 - virology
Cytokine storm
Cytokines
Evaluation
Female
Health risks
HScore
Humans
Inflammation
Interleukin 1 receptor antagonist
Interleukin 1 Receptor Antagonist Protein - therapeutic use
Lymphocytosis
Male
Middle Aged
Morbidity
Mortality
MuLBSTA
Oxygen
Oxygen - administration & dosage
Pandemics
Pandemics - prevention & control
Pathogenesis
Patients
Pneumonia - drug therapy
Secondary infection
Severity of Illness Index
Side effects
SOFA
Viral diseases
Viremia
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:COVID‐19 pandemic has been affecting the whole world by increasing morbidity and mortality rates day by day. Treatment algorithms have been attempted as parallel to the increasing experience with COVID‐19. In the pathogenesis of this virus pro‐inflammatory cytokine storm has been called to have the main role. The right timing should be made for treatments. We proposed IL‐ 1 blocking by anakinra in seventeen COVID‐19 patients at high risk of worsening. Patients were assessed according to HScore, SOFA (Sequential Organ Failure Assessment Score = SOFA), MuLBSTA Score (multilobular infiltration, hypo‐lymphocytosis, bacterial coinfection, smoking history, hyper‐tension, and age), Brescia‐COVID respiratory severity scale (BCRSS). In our study, the mortality rate was 17.6%. Consequently, 1 (5.9%) patient was receiving low‐flow oxygen supply, 3 (17.6%) patients needed no longer oxygen supply and 10 (58.8%) patients were discharged from the hospital. According to the results of our study in the manner of general evaluation; we found that SOFA, MuLBSTA, and BCRSS scores were one step ahead according to HScore being insufficient to determine early phases of the disease. In our opinion, the prominent factors that emphasize the use of anakinra could be listed as comorbidity, risk, or presence of secondary infection, ongoing malignant disease. However, the other factors that enhance the use of anakinra in the situation of viremia also could be sorted as no response to full dose antivirals, antiviral side effects, or no success to antiviral treatment.
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.26473